33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Geometric network analysis defines poor-prognosis subtypes in multiple myeloma
    Meeting Abstract

    Simhal, A. K.; Maclachlan, K. H.; Elkin, R.; Zhu, J.; Usmani, S.; Keats, J. J.; Norton, L.; Deasy, J. O.; Oh, J. H.; Tannenbaum, A.
    Blood (2022)

    Fulltext@MSK | Save
  • International Working Group (IWG) response criteria and association with overall survival in patients with myelodysplastic syndromes treated with hypomethylating agents - A systematic review and meta-analysis
    Meeting Abstract

    Bewersdorf, J. P.; Grimshaw, A.; Platzbecker, U.; Fenaux, P.; Sekeres, M. A.; Zeidan, A. M.; Stahl, M. F.
    Blood (2022)

    Fulltext@MSK | Save
  • Circulating tumor plasma cells in the screened iStopMM smoldering multiple myeloma cohort
    Meeting Abstract

    Thorsteinsdóttir, S.; Oskarsson, J. Þ.; Rögnvaldsson, S.; Gíslason, G.; Aspelund, T.; Sigurdardottir, G. Á; Thordardottir, Á. R.; Vidarsson, B.; Onundarson, P. T.; Agnarsson, B. A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Evaluating stem cells to predict post-transplant relapse in the myelodysplastic syndromes
    Meeting Abstract

    Kroger, B.; Huang, Y.; Patel, P.; Afrough, A.; Kaur, G.; Anderson, L. D. Jr; Awan, F. T.; Ramakrishnan, P.; Verma, K.; Vittrup, R.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Outcomes of therapies and resistance mutations following non-covalent Bruton's Tyrosine Kinase inhibitor treatment for patients with chronic lymphocytic leukemia and Richter Transformation
    Meeting Abstract

    Thompson, M. C.; Coombs, C. C.; Roeker, L. E.; Jensen, J. L.; Shah, N. N.; Luo, T.; Patel, K.; Bailey, N.; Fakhri, B.; Eyre, T. A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Incidence, clinical associations, and co-mutation patterns of UBA1 mutations in MDS
    Meeting Abstract

    Sirenko, M.; Bernard, E.; Beck, D. B.; Creignou, M.; Domenico, D.; Farina, A.; Arango, J. E.; Kosmider, O.; Hasserjian, R. P.; Jadersten, M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Pelabresib (CPI-0610) as add-on to ruxolitinib in myelofibrosis: Durability of response and safety beyond week 24 in the phase 2 MANIFEST study
    Meeting Abstract

    Harrison, C.; Kremyanskaya, M.; Bose, P.; Gupta, V.; Rampal, R. K.; Lambert, J.; Talpaz, M.; Vannucchi, A.; Kuykendall, A.; Kiladjian, J. J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Five-year overall survival analysis using first- and second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase in a prospective observational study (SIMPLICITY)
    Meeting Abstract

    Mauro, M.; Paquette, R.; Hehlmann, R.; Williams, L. A.; Goldberg, S. L.; Michallet, M.; Gambacorti-Passerini, C.; Tang, D.; DeGutis, I. S.; McBride, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Clinical response to azacytidine (AZA) is associated with increased contribution from mutated blood progenitors: Insights from single cell genotyping of matched stem/progenitor and mature blood cells from MDS/CMML patients pre- and post-AZA treatment
    Meeting Abstract

    Thoms, J. A. I.; Schnegg-Kaufmann, A.; Bhuyan, G. S.; Hampton, H. R.; Vaughan, L.; Rutherford, K.; Kakadia, P. M.; Lee, H. M.; Johansson, E.; Failes, T. W.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL): Final results of a phase Ib/II randomized study and single-arm extension (Ext) study
    Meeting Abstract

    Sehn, L. H.; Hertzberg, M.; Opat, S.; Herrera, A. F.; Assouline, S.; Flowers, C. R.; Kim, T. M.; McMillan, A. K.; Özcan, M.; Safar, V.; more...
    Blood (2022)

    Fulltext@MSK | Save